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The liver-specific expression of the GLUT2 glucose transporter
gene is suppressed in cultured hepatoma cell lines as well as in
hepatocytes in primary culture. To understand the underlying
mechanism involved in this process, we analysed the rat GLUT2
promoter region. A DNase I footprinting assay with rat liver
nuclear extract revealed eight protected regions within a ®500 bp
region of the GLUT2 promoter (sites A to H). Three of these
sites (B, F and H) were occupied by transcription factors that are
considerably enriched in liver cells compared with spleen or
kidney. The proteins binding to these sites were investigated by
a combination of DNase I footprinting assay and electrophoretic
mobility-shift assay with the addition of specific oligonucleotide
competitors and specific antibody against known transcription
factors. As a result it was revealed that hepatocyte nuclear factor
3 binds to site B (®120 to ®70), and CCAAT}enhancer binding
protein α (C}EBPα) and C}EBPβ bind to site F (®375 to ®356)
and site H (®500 to ®471). The binding of C}EBP to sites F and
H was markedly decreased within 4 h when liver cells were
INTRODUCTION
Cellular differentiation requires the precise and tightly controlled
appearance and interplay of various transcription factors. The
tissue-specific transcription factors as well as ubiquitous factors
are involved in the initiation and maintenance of the transcription
of a range of genes in a cell-specific manner. In recent years,
several transcription factors that might be involved in the
transcription of liver-specific genes, such as albumin, α-
fetoprotein, α
"
-antitrypsin, transthyretin and transferrin, have
been discovered and characterized [1,2]. Hepatocyte nuclear
factor 1 (HNF-1) [3,4], HNF-3 [5,6], HNF-4 [5,7] and the
CCAAT}enhancer binding protein (C}EBP) [8–10] are the major
liver-enriched trans-acting factors that have key roles in the
transcriptional regulation of genes in liver cells. The possible
roles of these transcription factors in the progression through
different stages of hepatic cell commitment and differentiation
are under discussion [11].
The role of C}EBP in tissue growth and differentiation has
drawn special attention. C}EBP is expressed abundantly in liver
and fat cells [12] and is considered to have a direct role in
regulating the transcription of some enzymes involved in con-
trolling the metabolic pathways of carbohydrates and lipids [13].
It has also been suggested that C}EBPα is a key factor in the
differentiation of preadipocytes into fat cells [14]. A decrease in
Abbreviations used: CAT, chloramphenicol acetyltransferase ; C/EBP, CCAAT/enhancer binding protein ; EMSA, electrophoretic mobility-shift assay ;
HNF, hepatocyte nuclear factor.
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subjected to primary culture, suggesting that C}EBP might be
responsible for the decreased expression of GLUT2 in this
process. In contrast, Western blot analysis revealed that C}EBPα
began to decrease after 1 h of hepatocyte culture, and C}EBPβ
was not changed significantly throughout the culture period,
suggesting that C}EBP could be regulated at the transcriptional
level as well as the post-translational level when hepatocytes were
put in culture. To confirm the role of C}EBP in the regulation of
GLUT2 promoter activity, sites F and H were ligated to a
chloramphenicol acetyltransferase (CAT) reporter gene and co-
transfected with a C}EBP expression vector into HepG2 cells.
The co-expression of C}EBPα and C}EBPβ resulted in 9.1-fold
and 3.8-fold increases of CAT activities in the site F-CAT and
site H-CAT constructs respectively. These results indicate that
C}EBPα and C}EBPβ regulate the promoter activity of the
GLUT2 gene and might be responsible for the down-regulation
of the GLUT2 gene when hepatocytes are subjected to primary
culture.
the level of C}EBPα mRNA species has been observed in
primary cultured hepatocytes [15], suggesting a role for C}EBPα
in the maintenance of the quiescent, mature state of adult
hepatocytes [16].
One of the most important functions of the liver is the
regulation of glucose metabolism. Hepatic glucose production
and utilization involves the regulation of many kinds of gene,
such as those for glucokinase, pyruvate kinase, 6-phosphofructo-
2-kinase}fructose-2,6-bisphosphatase and phosphoenolpyruvate
kinase. The liver-enriched transcription factors also interact with
cis-elements of these genes, which mediate the regulation of the
genes’ expression after hormonal or metabolic stimulation [17].
Hepatic glucose metabolism begins or ends with the movement
of glucose into or out of the hepatocyte. This transport of
glucose through the membrane of liver cells is accomplished by
a specific facilitative transporter, GLUT2 [18,19]. This type of
glucose transporter is expressed mainly in liver cells and has a
higher K
m
than other types [20]. Pancreatic β-cells also express
GLUT2, although the regulation of this molecule differs in a
manner related to the functions of two cell types [21,22].
Although many genes referred to as being liver-specific are
transcribed exclusively or preferentially in liver, the hepatic
expression of the GLUT2 gene shows some additional features
not generally found in liver-specific genes. GLUT2 is expressed
early in liver, before the appearance of glucokinase, increases
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throughout the developmental stages and becomes the main
glucose transporter in fully differentiated liver cells [23]. However,
GLUT2 fails to be transcribed in established hepatoma cells such
as HepG2 [19,24] or in cultures of primary hepatocytes, in which
the expression of other liver-specific genes is maintained [25–27].
This phenomenon suggests that the GLUT2 gene might be
regulated not only in a tissue-specific manner but also by the
differentiation status of liver cells. Therefore studies on the gene
regulation of GLUT2 might provide an insight into the molecular
mechanism of expression of the liver-specific gene. So far the
interactions of transcription factors on many liver-specific genes
have been studied to improve our understanding of tissue-
specific expression; however, the molecular mechanism of tran-
scriptional regulation of GLUT2 expression in liver cells is as yet
largely unknown.
We previously reported the genomic organization and pro-
moter sequence of the rat GLUT2 glucose transporter gene [28].
We also showed that the same transcriptional unit is used in the
liver and in pancreaticβ-cells, although the regulatory mechanism
in response to a physiological signal in a living organism might
be different. In the present study we identified several DNA–
protein binding sites in this promoter and found that at least two
sites were bound by liver-enriched transcription factor C}EBP.
We also showed that C}EBP binding activity to GLUT2 pro-
moter was decreased during primary hepatocyte culture; finally
we showed that C}EBP could trans-activate the rat GLUT2 gene
promoter in hepatoma cell line HepG2. This result implies a
possible regulatory mechanism of GLUT2 promoter activity in
relation to the hepatocyte differentiation status and the ex-
pression of C}EBP.
MATERIALS AND METHODS
Preparation of nuclear extracts
Nuclear extracts from liver, spleen and kidney of male Sprague–
Dawley rats were prepared as described in [29]. Protein con-
centration was determined by the method of Bradford [30]. The
extracts were frozen in aliquots and stored at ®70 °C.
DNase I footprinting assay
DNA fragments of approx. 300 bp were labelled in one strand
and purified as follows. The promoter region was subjected to
combined treatment with HaeIII, HincII and AluI to obtain
overlapping promoter fragments ; the resulting fragments were
subcloned into pGEM-4Z vector. The promoter fragments were
isolated by double digestion with EcoRI (or HindIII) and PstI
(or KpnI) to obtain 5«-overhanging and 3«-overhanging ends. The
fragments were labelled with Klenow fragment and [α-$#P]dATP,
then purified by PAGE. DNA–protein binding reactions were
performed with 50000 c.p.m. (approx. 1 ng) of probe per reaction
in a solution containing 10 mM Hepes, pH 7.9, 60 mM KCl, 7%
(v}v) glycerol, 1 mM EDTA, 1 mM dithiothreitol, 2 µg of
poly(dI-dC)[poly(dI-dC) and the indicated amount of nuclear
extract. After 30 min of incubation on ice, 5 µl of DNase I,
freshly diluted in a solution containing 10 mM Hepes, pH 7.9,
60 mM KCl, 25 mM MgCl
#
, 5 mM CaCl
#
and 7% (v}v) glycerol,
was added to the reaction, which was then kept at room
temperature for 2 min. Dilutions of DNase I ranged from 1:200
to 1:2000 of stock (10 units}µl), depending on the amount of
protein in the reaction. Digestion reactions were stopped by the
addition of 80 µl of a stop solution containing 20 mM Tris}HCl,
pH 8.0, 20 mM EDTA, 250 mM NaCl, 0.5% SDS, 4 µg of yeast
tRNA and 10 µg of proteinase K. The samples were incubated
for 30 min at 45 °C, extracted with phenol}chloroform, precipi-
tated with ethanol and resuspended in formamide dye. The
samples were resolved in 6% (w}v) polyacrylamide}7 M urea
sequencing gel. The protected regionsweremappedwith reference
to the migration of Maxam–Gilbert A­G sequencing products.
For the competition assay, 1.5 pmol of oligonucleotides for
specific transcription factors were added to the binding reactions ;
40 µg of nuclear extract was used per reaction. The oligo-
nucleotides for HNF-1 [31], HNF-3 [5], HNF-4 [7], HNF-5 [32],
C}EBP [9] and NF-Y [33] were synthesized; AP-1, Oct-1 and
TFIID consensus oligonucleotides were purchased from
Promega.
Electrophoretic mobility-shift assay (EMSA) and supershift assay
The oligonucleotides used in these assays were as follows: site F,
5«-GCCTCTACTCTTATCTGACTCAACAGG-3« ; site H, 5«-
AGTTAACAATCTTGATTTCCACATCACAAACGTGCA-
3«. The formation of protein–DNA complexes was induced by
the same procedure as for the DNase I footprinting assay. After
30 min on ice, the samples were resolved in 4% (w}v) non-
denaturing polyacrylamide gel polymerized in 0.25¬TBE (where
TBE is Tris}borate}EDTA). For competition assays, a 100–200-
fold molar excess of various unlabelled competitor DNA species
was added to the reaction mixture before the addition of nuclear
extracts. For the supershift assay, 1 µg of anti-C}EBPα, anti-
C}EBPβ or anti-C}EBPδ (SantaCruz Biotech) was added to the
DNA–protein binding reaction. The dried gels were exposed to
X-ray film at ®70 °C with an intensifying screen.
Primary hepatocyte culture and nuclear extract preparation
Hepatocytes were isolated from male Sprague–Dawley rats
(approx. 200 g) by the collagenase perfusion method [34]. Dis-
sociation into individual hepatocyteswas performed inWilliams’s
E medium containing 5 mM glucose, 0.1 i.u}ml insulin, 10 nM
dexamethasone, 10% (v}v) fetal calf serum, 26 mM sodium
bicarbonate, 100 i.u.}ml penicillin G, 100 µg}ml streptomycin
and 0.25 µg}ml amphotericin B. The cells were filtered through
four layers of gauze and centrifuged at 50 g for 4 min. The pellets
were washed twice with 40 ml of medium and subjected to
Percoll density-gradient centrifugation. The pellets, which were
composed of viable hepatocytes, were suspended in modified
Williams’s E medium described above. For each hepatocyte
preparation the cell viability was estimated by the exclusion of
Trypan Blue. Hepatocytes (10)) were plated on 10 cm dishes in a
final volume of 10 ml of medium and maintained at 37 °C in an
air}CO
#
(19:1) atmosphere. Nuclear extracts were prepared by
the method of Schreiber et al. [35] at the designated time point of
hepatocyte maintenance.
Construction of plasmids
The region containing site A (­56 to ­189) was obtained by
digesting the promoter with AccI and EcoRI, subcloned into
pCAT3 basic vector and named pCAT(­56}­189). pCAT-
F(­56}­189) or pCAT-H(­56}­189) was constructed as
follows. Site F and site H double-stranded oligonucleotides were
subcloned into pT7Blue(R) vector, and the resulting recombinant
DNA species were treated with KpnI and XbaI to obtain site F
or site H. The fragments were inserted into the KpnI and NheI
site of pCAT(­56}­189). The constructs were confirmed by
DNA sequencing in both directions.
To study the role of C}EBP on GLUT2 promoter activity,
pMSV-C}EBPα or pMSV-C}EBPβ (kindly donated by Dr. S.
McKnight), which are the overexpression vectors of C}EBPα or
C}EBPβ, was used for transfection.
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Figure 1 DNase I footprinting assay of the rat GLUT2 promoter region
DNase I footprinting assay was performed as described in the Materials and methods section with the indicated amounts (in µg) of nuclear proteins from liver, kidney and/or spleen. The probes
used were 32P-end-labelled fragments of : ­190 to ®149, coding strand (A) ; ­2 to ®275, non-coding strand (B) ; ®150 to ®444, non-coding strand (C) ; ®150 to ®444, coding
strand (D) ; and ®328 to ®552, coding strand (E). The lane headed A­G contained Maxam–Gilbert sequencing products. Nucleotide numbers refer to the positions with respect to the previously
reported promoter region [28] ; position ®1 represents the nucleotide preceding the start of transcription. The protected regions are indicated by boxes with their names and positions (sites A
to H) ; liver-specific protected regions are marked by black boxes. The experiments were also performed with labelling of the opposite strand of each probe to confirm the protected regions (results
not shown).
Cell culture, DNA transfection and chloramphenicol
acetyltransferase (CAT) assay
Cells (10&) of the human hepatoma cell line HepG2 were spread
in 6 cm plates and cultured at 37 °C in Earle’s minimal essential
medium (MEM) with 10% (v}v) fetal calf serum. After 1–2 days
of culture, various CAT constructs were transfected with lipo-
fectin reagent. In brief, 3 µg of CAT constructs, 1.5 µg of pMSV-
C}EBPα and}or pMSV-C}EBPβ, 1 µg of pCMV-β-galactosidase
and 15 µl of lipofectin in 2 ml of OPTI-MEM I medium lacking
serum were mixed and added to the HepG2 cells. To transfect
constant amounts of DNA, sample DNA species were supple-
mented with an appropriate control vector. After a 15 h in-
cubation period the remaining liposome–DNA complexes were
removed and the medium was replaced with serum-containing
medium; 72 h after transfection, cells were scraped and
resuspended in 100 µl of 0.25 M Tris}HCl, pH 7.8, and disrupted
by freezing and thawing. The reactions were centrifuged at
10000 g for 30 s, after which the extracts were collected. Aliquots
of 30 µl were used for β-galactosidase assay, whereas aliquots of
2 µl were used for measurement of protein concentration. The
remaining aliquots were heat-treated at 65 °C for 10 min. For
the measurement of CAT activities, the amounts of cell extract
to be loaded on a TLC plate were normalized with respect
to β-galactosidase activities and protein concentrations. The
CAT activities were expressed as percentage conversion into
acetylated chloramphenicol from chloramphenicol.
Western blot analysis
Nuclear extracts (30 µg) prepared from indicated time points of
primary hepatocyte culture were subjected to SDS}PAGE [12%
(w}v) gel], transferred to nitrocellulose membranes and detected
by enhanced chemiluminescence (ECL, Amersham) [36] with
anti-C}EBPα and anti-C}EBPβ as primary antibodies
(SantaCruz Biotech).
Statistical analysis
All transfection studies were performed in three separate experi-
ments in which triplicate dishes were transfected. The results are
given as means³S.E.M. Statistical analysis was performed with
SigmaStat software (Jandel Scientific).
RESULTS
Identification of the protein-binding sites in the rat GLUT2 gene
promoter
Previously we cloned the promoter of the rat GLUT2 gene [28].
In the present study we performed DNase I footprinting experi-
86 J.-w. Kim and Y.-h. Ahn
Figure 2 Summary of protein-binding regions in the rat GLUT2 promoter
The transcription initiation site is designated ­1 [28]. The boxed areas represent the protected regions of rat GLUT2 promoter identified by DNase I footprinting assay with rat liver nuclear extract.
The known consensus sequences are underlined and their names are given underneath.
Figure 3 DNase I footprinting competition experiments
DNase I footprinting assay with liver nuclear extracts (NE, 40 µg of protein) in the absence or presence of a 200-fold molar excess of competing oligonucleotides (CO) for known transcription
factors, as indicated above each lane. The probes used were 32P-end-labelled fragments of ­2 to ®275 (A) and ®328 to ®552 (B and C). The lane marked A­G was the Maxam–Gilbert
sequence ladder. The protected regions are indicated by open boxes with their names and positions, and liver-specific protected regions are marked by filled boxes.
ments to localize the DNA sequences able to interact with trans-
acting factors within the region ­190 to ®732 nt. The ex-
periment with rat liver nuclear extracts showed eight protected
regions, which we designated as follows: site A (­63 to ­110),
site B (®120 to ®70), site C (®204 to ®134), site D (®231 to
®213), site E (®325 to ®290), site F (®375 to ®356), site G
(®438 to ®417) and site H (®500 to ®471) (Figures 1 and 2).
DNase I footprinting experiments with rat kidney or spleen
nuclear extracts showed different patterns of protection in three
regions (Figure 1). Therefore sites B, F and H were regarded as
liver-enriched trans-acting protein-binding sites. Computer
analysis of these sites revealed that site B was compatible with
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Figure 4 EMSA of sites H and F
(A, B) EMSA with site H (A) or site F (B) oligonucleotide as a probe with liver nuclear extract
(NE ; 10 µg of protein per reaction) was performed in the absence or presence of 100-fold molar
excess of competing oligonucleotides (CO) for known transcription factors, as indicated at the
top of each lane. (C) EMSA with C/EBP consensus [9] as a probe. 32P-labelled C/EBP
oligonucleotide was incubated with the indicated amounts (in µg) of liver nuclear extract (NE)
in the absence or presence of a 100-fold molar excess of unlabelled C/EBP, site F or site H
oligonucleotide (CO), as indicated at the top of the lanes.
binding sites for the HNF-3, site F had a perfect matched
sequence for AP-1, and site H had the consensus sequences for
both C}EBP and Oct-1 (Figure 2). Although site A did not con-
tain a TATA box, it contained an initiator (Inr) sequence [37]
that is known to be a binding site for general transcription
factors including RNA polymerase. The protein binding sites are
summarized in Figure 2.
Determination of the transcription factors bound to liver-specific
DNA elements in rat GLUT2 promoter
To investigate the nature of liver-specific proteins binding to sites
B, F and H, we first performed a competition assay with
oligonucleotides corresponding to binding sites for known tran-
scription factors. As shown in Figure 3(A), the addition of HNF-
Figure 5 Supershift assay of sites H and F with anti-C/EBP antibodies
Labelled site H (A) or site F (B) was incubated with rat liver nuclear extract (NE, 10 µg) in
the absence or presence of anti-C/EBPα and/or anti-C/EBPβ antibody (Ab), as indicated above
the lanes, and the resulting complexes were subjected to electrophoresis in 4% (w/v) non-
denaturing gel. The DNA–protein complexes are indicated by filled arrows ; the positions of
supershifted DNA–protein–antibody complexes are indicated by open arrows. No supershift
was observed in the experiment with the addition of anti-C/EBPδ antibody to both sites (results
not shown).
3 or HNF-5 competitors markedly inhibited the protection of the
®105 to ®120 region in site B. In this regard, the HNF-3 family
recognizes two apparently unrelated DNA sequence motifs, and
one of them is included in the binding site consensus sequence for
HNF-5 [32]. Roux et al. [38] reported that the sequences
for HNF-3 displayed a common feature and moreover that the
DNA-binding specificities of HNF-3 and HNF-5 were identical.
Our results also showed that HNF-3 and HNF-5 bound to the
same sequence of the rat GLUT2 promoter. Another liver-
specific protected region, site F, competed with C}EBP consensus
oligonucleotide (Figure 3B). This was somewhat unexpected
because computer analysis showed that site F matched with the
AP-1 binding site (Figure 2). The addition of AP-1-binding site,
however, failed to compete with protein binding for site F
(Figure 3B). Site H had the sequences for binding C}EBP or Oct-
1, but only C}EBP oligonucleotide outcompeted the protection
(Figure 3C). These results were further confirmed by EMSA
experiments : EMSA of site H revealed three shifted bands
(Figure 4A), and slowly migrating bands were displaced not by
Oct-1 competitor but by C}EBP competitor. Site F also showed
C}EBP binding, but the binding was less strong than that exerted
by site H (Figure 4B). This result was confirmed by the experiment
with $#P-labelled C}EBP oligonucleotide as a probe. The un-
labelled form of site F or site H, as well as C}EBP oligonucleotide
itself, could outcompete the binding of nuclear proteins to
C}EBP probe (Figure 4C).
Binding of C/EBPα and C/EBPβ to sites H and F
The binding of C}EBP to the GLUT2 promoter was further
investigated by a supershift experiment with antibodies against
C}EBPα, C}EBPβ and C}EBPδ. As shown in Figure 5, super-
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Figure 6 Binding of C/EBP to sites H and F decreased during primary
hepatocyte culture
Hepatocytes were cultured for 10 h and nuclear extracts were prepared at the indicated time
points as described in the Materials and methods section. For EMSA, 10 µg of nuclear extracts
(NE), prepared at each time point of culture as indicated, was incubated with 32P-labelled NF-
Y [33] consensus double-stranded oligonucleotide (A), site H (B) or site F (C) as a probe. For
supershift assay, the nuclear extracts were incubated with anti-C/EBPα or anti-C/EBPβ
antibody (Ab) for 10 min before the addition of the probe. The reaction mixtures were subjected
to non-denaturing PAGE (4% gel). The DNA–protein complexes are indicated by filled arrows ;
the positions of supershifted DNA–protein–antibody complexes are indicated by open arrows.
shifted bands appeared when anti-C}EBPα or anti-C}EBPβ
antibody was added to the binding reaction with site H or site F.
The supershifted bands were more evident in site H.
Binding of C/EBP to rat GLUT2 promoter decreased during
culture of primary hepatocytes
During primary culturing of hepatocytes, the cells were harvested
for nuclear extract preparation at the indicated time points.
First, EMSA experiments were performed with an NF-Y oligo-
nucleotide, which binds the ubiquitous NF-Y proteins as an
internal control of protein [33,39]. The binding of DNA by this
transcription factor was not changed significantly during a 10 h
culture period (Figure 6A). In contrast, C}EBP binding to sites
H and F showed a marked change between 1 and 4 h after the
hepatocytes were put in culture (Figures 6B and 6C). These
results suggested that decreased C}EBP expression might be
Figure 7 Western blot analysis of C/EBP proteins during primary
hepatocyte culture
Primary hepatocyte nuclear extracts (30 µg) prepared from the indicated time points of culture
were resolved by SDS/PAGE (12% gel) and either stained with Coomassie Brilliant Blue
(A) or transferred to a nylon membrane. The membrane was blocked with 5% (w/v) non-fat dried
milk, and incubated with 1 : 2000 diluted anti-C/EBPα (B) or anti-C/EBPβ (C) (SantaCruz
Biotech) as a primary antibody. Horseradish peroxidase-conjugated anti-(rabbit IgG) horse
radish peroxidase conjugated antibody was used as a secondary antibody (diluted 5000-fold),
and detected with an enhanced chemilumineiscence (ECL) system. Arrows indicate the protein
components of C/EBPα or C/EBPβ. Abbreviations : LAP, liver-activating protein ; LIP,
liver-inhibitory protein.
partly responsible for the GLUT2 gene expression known to be
decreased when hepatocytes were subjected to primary culture.
To correlate the change of protein amount in C}EBP with its
binding to site H or site F during primary culture, the nuclear
extracts used for EMSA at the indicated incubation times were
subjected to Western blot analysis. During this period, total
protein concentrations remained unchanged (Figure 7A). As
reported previously, immunoblotting with anti-C}EBPα anti-
body showed three major protein bands of 43, 40 and 30 kDa
[40]. These proteins decreased markedly after 1 h of culture, and
showed a gradual decrease after that (Figure 7B). Liver-activating
protein (36 kDa) and liver-inhibitory protein (21 kDa), which
constitute C}EBPβ, did not change notably (Figure 7C).
Overexpression of C/EBPα and C/EBPβ resulted in an increase of
promoter activity in HepG2 cells
TheGLUT2gene has been reported to be suppressed in hepatoma
cell lines such as HepG2 cells as well as in primary cultured
hepatocytes. From the experiments described above, the
decreased binding of C}EBPs to GLUT2 promoter in these cells
was thought to be responsible for decreased GLUT2 gene
expression; if this were so the overexpression of C}EBP should
restore the GLUT2 promoter activity. To examine this possibility
we constructed the plasmid containing site H or site F in front of
a minimal promoter of the GLUT2 gene in pCAT3-basic vector,
and examined their activity when C}EBPα and}or C}EBPβ was
overexpressed in HepG2 cells. The CAT reporter assay showed
definite trans-activation by C}EBP on sites H and F, and the
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Figure 8 Effect of C/EBP overexpression on the GLUT2 promoter activity
(A) Plasmid constructs used in CAT assay. pCAT(­56/­189) was used for the minimal promoter element, and pCAT-H(­56/­189) and pCAT-F(­56/­189) were constructed as described
in the Materials and methods section. (B) Effects of C/EBP overexpression on the promoter activity of the GLUT2 promoter. HepG2 cells (105 cells) were co-transfected with each CAT
construct, with or without pMSV-C/EBPα and/or pMSV-C/EBPβ, as indicated ; 72 h after transfection, cells were scraped and the CAT activities were measured by TLC.
All results were normalized with respect to β-galactosidase activities and protein concentrations, and were calculated as percentage conversions into acetylated chloramphenicol from
chloramphenicol. The result is shown as relative CAT activities compared to that of pCAT(­56/­189) without C/EBP overexpression.
interaction of C}EBPα and C}EBPβ was found to be synergistic
in this promoter (Figure 8). The activities of the site H-CAT and
site F-CAT constructs were increased 9.1-fold and 3.8-fold
respectively when pMSV-C}EBPα and pMSV-C}EBPβ were co-
transfected in HepG2 cells, suggesting that C}EBP is one of the
main regulators of liver-specific expression of the GLUT2 gene.
DISCUSSION
When hepatocytes were cultured in itro, GLUT1 mRNA
increased markedly within a few hours with a significant decrease
in GLUT2 during the initial 24 h culture period, whereas albumin
mRNA remained unchanged during this short-term culture [27].
In this cellular adaptation process, specific elements responsible
for the down-regulation of GLUT2 mRNA in cultured or de-
differentiated cells were unknown. The interest in the present
study was to investigate the interplay between the DNA-binding
protein and the GLUT2 promoter, which is involved in the
suppression of GLUT2 gene expression in this phenomenon. The
pattern of decrease in GLUT2 expression in the time course of
the culture can vary with the conditions of culture, so we
maintained the same culture environment and same nuclear
extracts throughout the study. The GLUT2 promoter has two
binding sites for the liver-enriched transcription factor C}EBP,
and the binding of C}EBP to the GLUT2 promoter was
significantly decreased during short-term culture of the hepato-
cyte, suggesting that this decrease in interaction is responsible for
the decreased expression of GLUT2 in this process.
The fact that C}EBP regulates GLUT2 promoter activity
provides a significant insight into hepatocyte differentiation. In
liver, C}EBPα mRNA has been observed to decrease when
hepatocytes are grown in culture or during liver regeneration
[15], as well in as a hepatoma-derived cell line such as HepG2
[41]. Taking this together with the fact that GLUT2 mRNA was
down-regulated during primary hepatocyte culture [27], we
suggest a special role for C}EBPα in the appearance of GLUT2
in the hepatocyte differentiation programme as well as in the
regulation of GLUT2 gene transcription in response to physio-
logical stimuli in fully differentiated hepatocytes. It was also
reported that C}EBPβ controls the down-regulation of albumin
gene transcription during liver regeneration [42]. It was suggested
that C}EBPβ, while enhancing the transcription of cell-cycle-
related genes and controlling the G
"
}S checkpoint, down-
regulates albumin synthesis to prepare the hepatocyte for entry
into the cell cycle during liver regeneration. In the present study,
the maximal transcriptional activity of the GLUT2 gene pro-
moter was observed when pMSV-C}EBPα and pMSV-C}EBPβ
were co-transfected. Unlike the albumin gene, increasing the
amount of pMSV-C}EBPβ did not yield a significant difference
between experimental groups (results not shown), suggesting
that C}EBPα and C}EBPβ trans-activate the GLUT2 promoter
in a synergic manner.
The present study indicates the possible role of C}EBP in the
decreased expression of the GLUT2 gene in primary culture.
C}EBP binding activity to the GLUT2 promoter was strikingly
decreased when the liver cell was subjected to primary culture.
The binding of C}EBPα or C}EBPβ to sites F and H was
decreased after 4 h of culture, whereas the amount of C}EBPα
protein itself began to decrease after 1 h of culture. Moreover,
little change in C}EBPβ protein content was observed during the
culture period. This discrepancy could be explained in part by
post-translational modification. It was reported that the
phosphorylation status and the DNA-binding activity of the
transcription factor could be regulated on terminal differentiation
of the liver [43]. This implies the possibility that many tran-
scription factors might be regulated by changes of the protein
modification in the differentiation process. In fact, C}EBPβ is
activated by phosphorylation, leading to the inactivation of an
inhibitory domain [11,44], which also affects the DNA-binding
activity [45]. The role of phosphorylation of C}EBPα in the
transcriptional control of genes is more obscure, although the
phosphorylation of C}EBPα by protein kinase C or MAP kinase
resulted in an attenuation of site-selective DNA binding in itro
[46]. Our result indicates that the regulation of C}EBP could be
achieved by its protein expression as well as its modification in
controlling GLUT2 promoter activity when hepatocytes were
put in culture, and possibly in the differentiation process. In
other words, the phosphorylation status of C}EBP might be
altered in response to extracellular signals during primary
hepatocyte culture, leading to a decreased binding of C}EBP to
its cognate sequence.
Another possible mechanism that affects the DNA-binding
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activity of C}EBP to the GLUT2 gene is the interaction with
other transcription factors. C}EBP belongs to the basic leucine
zipper (bZip) family and forms a homodimer or heterodimer for
DNA binding [47]. Analysis of the C}EBP sites within the
diverse population of genes shows a significant degree of varia-
bility between DNA sequences [11]. Regulation of the C}EBP-
DNA binding activity can be affected by the ability of each
C}EBP protein to dimerize with other members of the C}EBP
family and also with other nuclear factors [40]. In the present
study, even though both sites F and H can bind C}EBP, their
DNA sequences are quite different (Figure 2). Moreover,
their C}EBP-binding affinities (Figures 4 and 5) and trans-
activation potentials (Figure 8) were also different, suggesting
that the two sites (F and H) could be regulated differently by
C}EBP depending on the cellular status.
We demonstrated the presence of C}EBP-binding sites in the
rat GLUT2 promoter. In addition, we showed that the expression
of C}EBPα and C}EBPβ restored the transcriptional activity of
the GLUT2 gene, which was suppressed in HepG2 cells. In
conclusion, lower levels of C}EBP in cultured hepatocytes or
established cell lines might be responsible for decreased GLUT2
gene expression.
Previous studies of the physiological expression of GLUT2 in
liver cells have been limited because the expression is not
maintained in cultured hepatocytes or liver-derived cell lines.
Recently it was reported that a cell line established by other
researchers could express GLUT2 with the maintenance of the
glucose responsibility [48]. Although the cell line was not
physiological in terms of insulin response [49], it will nevertheless
be interesting to determine the role of C}EBP in such a cell line.
A study of whether C}EBP can affect the pattern of expression
of the endogenous GLUT2 gene will also be interesting if the
roles of other transcription factors, including HNF-3, are clarified
as a whole. Our results will provide an insight into the molecular
mechanisms involved in the regulation of GLUT2 expression
during the development and differentiation of the liver cell.
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